US equities |
SPCX $166.83 ▲+4.95% NVDA $236.81 ▲+1.22% MU $1,064.32 ▼-0.98% TSLA $377.44 ▲+1.85% MSFT $526.54 ▲+1.74% SNDK $1,714.44 ▼-0.32% INTC $117.20 ▼-1.78% META $744.70 ▲+2.28%
FinancialContent

Articles published by Galera Therapeutics

News headline image
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces Board Approval of Complete Liquidation and Dissolution
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Adopts Limited Duration Stockholder Rights Agreement
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Expands Commercial Leadership Team
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera to Present at Piper Sandler Annual Healthcare Conference
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX
News headline image
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Tickers GRTX